Hydrazinecarboxamide

Hydrazinecarboxamide

SCHEMBL1464164

NNC(N)=O.Nc1cccc2ncccc12

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 1/20 0.53
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
MAPT P10636 2/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46
ALDH1A1 P00352 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HDAC6 Q9UBN7 1/20 0.43
NSD2 O96028 1/20 0.43
PABPC1 P11940 3/20 0.43
EIF4H Q15056 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 2/20 0.43
NR4A2 P43354 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL115674 0.84 NCF1 (0.72) NCF1MEN1KMT2ALMNAHTT
SCHEMBL29961464 0.84 NCF1 (0.72) NCF1MEN1KMT2ALMNAHTT
Hydrochloric Acid SCHEMBL29862816 0.82 NCF1 (0.69) NCF1MEN1KMT2ALMNAHTT
Ammonia Solution, Strong SCHEMBL14322575 0.82 NCF1 (0.69) NCF1MEN1KMT2ALMNAHTT
Hydrochloric Acid SCHEMBL6119015 0.82 NCF1 (0.69) NCF1MEN1KMT2ALMNAHTT
Hydrazinecarboxamide SCHEMBL1464078 0.77 MEN1 (0.46) NCF1MEN1KMT2ALMNAHTT
Pyrimidine SCHEMBL28845436 0.76 NCF1 (0.60) NCF1MEN1KMT2ALMNAHTT
Aniline SCHEMBL2858457 0.76 NCF1 (0.66) NCF1MEN1KMT2ALMNAHTT
SCHEMBL27489211 0.75 MEN1 (0.71) MEN1KMT2ALMNAHTTMAPT
SCHEMBL16572948 0.75 NSD2 (0.67) MEN1KMT2ALMNAHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871760-B2 [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators ROCHE PALO ALTO LLC (US) 2014-10-28 US disclosed
EP-2480545-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011033055-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-24 WO disclosed
US-20110071143-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS BROTHERTON-PLEISS CHRISTINE E 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071143-A1 FUSED TRIAZOLE AMINES AS P2X7 MODULATORS P2RX3, P2RX7, P2RX1 NCF1 1717/4885MEN1 3265/4885KMT2A 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.